INT23952

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1987
Last Reported 2011
Negated 2
Speculated 0
Reported most in Body
Documents 18
Total Number 18
Disease Relevance 4.76
Pain Relevance 5.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Cyp2d4) oxidoreductase activity (Cyp2d4) endoplasmic reticulum (Cyp2d4)
cellular_component (Cyp2d4) cytoplasm (Cyp2d4)
Anatomy Link Frequency
liver 3
hepatocytes 2
brain 1
portal vein 1
Cyp2d4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Desipramine 2 99.46 Very High Very High Very High
Dextromethorphan 56 99.38 Very High Very High Very High
Catechol-O-methyltransferase 10 99.00 Very High Very High Very High
Oxycodone 204 98.38 Very High Very High Very High
sSRI 77 98.36 Very High Very High Very High
Cholecystokinin 2 98.36 Very High Very High Very High
substance P 2 96.64 Very High Very High Very High
tricyclic antidepressant 18 94.60 High High
antidepressant 32 94.36 High High
Codeine 8 80.16 Quite High
Disease Link Frequency Relevance Heat
Injury 33 99.82 Very High Very High Very High
Autoimmune Hepatitis 676 98.48 Very High Very High Very High
Infection 68 98.32 Very High Very High Very High
Hepatitis C Virus Infection 172 97.92 Very High Very High Very High
Hepatotoxicity 10 96.04 Very High Very High Very High
Drug Induced Neurotoxicity 41 93.64 High High
Hepatitis D Virus Infection 4 92.56 High High
Chronic Hepatitis 56 92.28 High High
Renal Disease 4 91.84 High High
Poisoning 3 89.72 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The expression of CYP2D6 protein in the treated group was higher than that of the control group, as determined by Western blotting.
Gene_expression (expression) of CYP2D6 protein
1) Confidence 0.78 Published 2007 Journal Eur. J. Pharmacol. Section Abstract Doc Link 17651725 Disease Relevance 0 Pain Relevance 0.27
In humans, CYP2D6 is genetically polymorphic; the variable expression of brain CYP2D6 may result in interindividual differences in central drug and neurotoxin metabolism, possibly contributing to interindividual differences in drug effects and neurotoxicity.
Gene_expression (expression) of CYP2D6 in brain associated with drug induced neurotoxicity
2) Confidence 0.72 Published 1999 Journal Drug Metab. Dispos. Section Abstract Doc Link 10421620 Disease Relevance 0.09 Pain Relevance 0.15
Approximately 7-10 % of the population does not express functional CYP2D6; for them codeine have no analgesic effect.
Neg (not) Gene_expression (express) of CYP2D6
3) Confidence 0.68 Published 2004 Journal Tidsskr. Nor. Laegeforen. Section Body Doc Link 15334119 Disease Relevance 0 Pain Relevance 0
CYP2D6 is clinically important in the metabolism of up to 25% of all clinical drugs, including ?
Gene_expression (important) of CYP2D6
4) Confidence 0.67 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2994065 Disease Relevance 0.14 Pain Relevance 0.04
Dextromethorphan is widely used as a probe for CYP2D6 phenotyping and for the assessment of CYP2D6 activity [18].
Gene_expression (phenotyping) of CYP2D6 associated with dextromethorphan
5) Confidence 0.67 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2994065 Disease Relevance 0 Pain Relevance 0.17
The CYP 2D6 subenzyme metabolises numerous drugs, including many typical and atypical antipsychotics (e.g. risperidone), antiarrhythmics (e.g. flecainide), tricyclic antidepressants (e.g. imipramine and amitryptiline), antihypertensive drugs (e.g. some ?
Gene_expression (subenzyme) of CYP 2D6 associated with tricyclic antidepressant
6) Confidence 0.65 Published 2006 Journal International Journal of Clinical Practice Section Body Doc Link PMC1448696 Disease Relevance 0.09 Pain Relevance 0.36
The conversion of oxycodone to oxymorphone, as well as the conversion of noroxycodone to noroxymorphone are catalyzed by the liver enzyme cytochrome P4502D6 (CYP2D6) (Figure 1) (Kress 2005)
Gene_expression (catalyzed) of CYP2D6 in liver associated with oxycodone
7) Confidence 0.56 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936259 Disease Relevance 0 Pain Relevance 1.77
The conversion of oxycodone to oxymorphone, as well as the conversion of noroxycodone to noroxymorphone are catalyzed by the liver enzyme cytochrome P4502D6 (CYP2D6) (Figure 1) (Kress 2005)
Gene_expression (catalyzed) of cytochrome P4502D6 in liver associated with oxycodone
8) Confidence 0.56 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936259 Disease Relevance 0 Pain Relevance 1.76
Furthermore, specific periods of the life cycle were identified that display a higher number of genes with sex-specific expression which included putative toxicological susceptibility related genes (e.g., Cyp2d4, Cyp3a23/3a1, Gstm1, Slc22a8).
Gene_expression (expression) of Cyp2d4
9) Confidence 0.52 Published 2010 Journal BMC Genomics Section Body Doc Link PMC3012673 Disease Relevance 0.18 Pain Relevance 0
Recent convincing data demonstrated the expression of CYP2D6 on the surface of hepatocytes suggesting a pathogenetic role of anti-LKM-1 autoantibodies for the liver damage.
Gene_expression (expression) of CYP2D6 in liver associated with hepatotoxicity
10) Confidence 0.51 Published 2004 Journal J Autoimmune Dis Section Abstract Doc Link PMC544946 Disease Relevance 1.56 Pain Relevance 0
Anti-LKM-1 autoantibodies could be an exception to the above aspect since recent data have demonstrated the expression of CYP2D6 on the surface of hepatocytes, while AIH-2 has not been observed in individuals who are deficient for CYP2D6.
Gene_expression (expression) of CYP2D6 in hepatocytes associated with autoimmune hepatitis
11) Confidence 0.51 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.84 Pain Relevance 0.04
CYP2D6 and COMT are both polymorphic in humans, and differential expression of CYP2D6 isoforms leads to interindividual variations in the metabolism of serotonergic medications (e.g., SSRIs) (Charlier et al. 2003).
Gene_expression (expression) of CYP2D6 associated with catechol-o-methyltransferase and ssri
12) Confidence 0.50 Published 2006 Journal Psychopharmacology (Berl) Section Body Doc Link PMC1705495 Disease Relevance 0 Pain Relevance 0.19
Interestingly, CYP2D6 is not present in rats, which express a homologous but functionally distinct cytochrome P450 2D1 (Malpass et al. 1999; Maurer et al. 2000).
Neg (not) Gene_expression (present) of CYP2D6
13) Confidence 0.50 Published 2006 Journal Psychopharmacology (Berl) Section Body Doc Link PMC1705495 Disease Relevance 0 Pain Relevance 0.18
Under this context, Ma et al [118] showed that key residues of a major CYP2D6 epitope (316–327) are exposed on the surface of the molecule and may represent key targets for anti-CYP2D6 production.
Gene_expression (production) of anti-CYP2D6
14) Confidence 0.40 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.77 Pain Relevance 0
A prerequisite for both anti-LKM-1 production and the activation of pathogenetic mechanisms involved in liver injury, is the expression of CYP2D6 on the surface of the patients' hepatocytes.
Gene_expression (expression) of CYP2D6 in hepatocytes associated with injury
15) Confidence 0.40 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.69 Pain Relevance 0
A small increase in total exposure to desipramine was found suggesting that CYP2D6-mediated metabolism was mildly inhibited, but this was considered clinically insignificant (Khosravan et al 2005b).
Gene_expression (metabolism) of CYP2D6-mediated associated with desipramine
16) Confidence 0.30 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643102 Disease Relevance 0.22 Pain Relevance 0.10
Studies have shown that memantine produces minimal inhibition of CYP450 enzymes CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4, indicating that no pharmacokinetic interactions with drugs metabolized by these enzymes are expected.
Gene_expression (produces) of CYP2D6
17) Confidence 0.30 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654628 Disease Relevance 0.18 Pain Relevance 0.03
The isolated, spontaneously active portal vein of guinea pig was stimulated by the following compounds (the pD2 is given in parentheses): caerulein (CER, 8.02), cholecystokinin octapeptide (CCK-8, 7.59), substance P (SP, 4.68), and carbachol (5.37), whereas neurotensin (NT) was ineffective and angiotensin II (AII) produced inhibition.
Gene_expression (given) of pD2 in portal vein associated with cholecystokinin and substance p
18) Confidence 0.00 Published 1987 Journal Pharmacology Section Abstract Doc Link 2437599 Disease Relevance 0 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox